Department of Clinical Neurology, University of Oxford, Oxford, UK.
Nat Rev Neurol. 2009 Dec;5(12):672-82. doi: 10.1038/nrneurol.2009.178.
This Review summarizes the natural history studies on multiple sclerosis (MS) that have evaluated prognostic factors. Reassessment of prognostic factors is warranted, as our ability to offer patients a reliable prognosis is limited, yet we rely on this knowledge to appropriately design clinical trials and interpret their results. The selection criteria for studies to review included a geographical referral base, duration of at least 9 years, prospective design, and populations of at least 100 patients with MS. For all forms of MS combined, negative prognostic factors included progressive disease, and disability at 2 and 5 years. In relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS) combined, negative prognostic factors were the onset of progression, a higher relapse rate, greater disability in the first 5 years, a shorter interval to the second relapse, and the involvement of more systems. Additional negative factors include a shorter time to progression in SPMS and a faster rate of disability in the first 2 and 5 years in primary progressive MS (PPMS). Onset of progression, relapse rate and disability in the initial 5 years could be fruitful therapeutic targets; however, longer-term clinical trials will be required to justify these end points.
这篇综述总结了评估多发性硬化症(MS)预后因素的自然史研究。重新评估预后因素是有必要的,因为我们为患者提供可靠预后的能力有限,但我们依赖这些知识来合理设计临床试验并解释其结果。用于综述的研究选择标准包括地理转诊基础、至少 9 年的持续时间、前瞻性设计以及至少 100 名 MS 患者的人群。对于所有形式的 MS 合并,负性预后因素包括进行性疾病和 2 年和 5 年时的残疾。在复发缓解型多发性硬化症(RRMS)和继发性进展型多发性硬化症(SPMS)合并中,负性预后因素包括进展的起始、更高的复发率、前 5 年更高的残疾程度、第二次复发的间隔更短以及更多系统的受累。其他负面因素包括 SPMS 中的进展时间更短以及原发性进展型多发性硬化症(PPMS)中前 2 年和 5 年残疾的更快速度。进展的起始、复发率和最初 5 年的残疾程度可能是有前途的治疗靶点;然而,需要进行更长期的临床试验来证明这些终点的合理性。